-transparent.png){kind=logo}
One-hundred and seven patients with acute myelogenous leukemia (AML) ranging in age from 15 to 82 yr who were previously untreated, received a 70 day high-dose remission induction regimen consisting of daunorubicin, cytarabine, and thioguanine (TAD). Identical complete remission rates of 65% were observed for 33 patients 60 yr of age and older and for 74 patients age 15-59 yr. Median remission duration and survival were 14 mo and 22 mo for patients 60 yr and older, and 16 mo and 22 mo for patients 15-59 yr. These differences are not significant. These data indicate that older patients respond to intensive chemotherapy in a similar manner to younger patients with this disease.
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
January 1990,
Haematology and blood transfusion,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
February 2006,
Annals of oncology : official journal of the European Society for Medical Oncology,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
January 2001,
Polskie Archiwum Medycyny Wewnetrznej,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
December 1985,
Cancer treatment reports,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
January 2001,
Advances in therapy,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
July 1982,
Cancer treatment reports,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
October 2009,
Nihon rinsho. Japanese journal of clinical medicine,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
November 1989,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
March 2000,
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
K A Foon, and
J Zighelboim, and
C Yale, and
R P Gale
February 1989,
Seminars in oncology,
